Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea

Acta Obstetricia et Gynecologica Scandinavica

Volumn 85, Issue 2, 2006, Pages 207-211

  Liedman, Ragner ^a   Grant, Lee ^b   Igidbashian, Sarah ^a   James, Ian ^b   McLeod, Alison ^b   Skillern, Laurence ^b   Åkerlund, Mats ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Pfizer Global Research Clinical Research and Development ^*

Author keywords

Atosiban; Intrauterine pressure; Primary dysmenorrhea; Uterine ischemia markers; Vasopressin V1a antagonist

Indexed keywords

ATOSIBAN; BIOLOGICAL MARKER; PLACEBO; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; ARGIPRESTOCIN; DRUG DERIVATIVE; HORMONE ANTAGONIST; VASOPRESSIN DERIVATIVE; VASOPRESSIN RECEPTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DYSMENORRHEA; FEMALE; HUMAN; INTRAUTERINE PRESSURE; ISCHEMIA; MENSTRUATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; UTERINE TUBE LIGATION; VISUAL ANALOG SCALE; BLOOD; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME; UTERUS CONTRACTION;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DYSMENORRHEA; FEMALE; HORMONE ANTAGONISTS; HUMANS; ISCHEMIA; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME; UTERINE CONTRACTION; VASOPRESSINS; VASOTOCIN;

EID: 33645649897     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340500495082     Document Type: Article

References (19)

1. Åkerlund M, Andersson K-E, Ingemarsson I. Effects of terbutaline on myometrial activity, endometrial blood flow and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol. 1976;83:673-8.
2. Åkerlund M, Strömberg P, Forsling ML. Primary dysmenorrhoea and vasopressin. Br J Obstet Gynaecol. 1979;86:484-7.
3. Strömberg P, Åkerlund M, Forsling ML, Granström E, Kindahl H. Vasopressin and prostaglandin in premenstrual pain and primary dysmenorrhoea. Acta Obstet Gynecol Scand. 1984;63:533-8.
4. Ekström P, Laudanski T, Mrugacz G, Forsling M, Kindahl H, Åkerlund M. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment - effect on uterine contractility. Br J Obstet Gynaecol. 1992;99:680-4.
5. th International Conference on the Neurohypophysis 1990; p. 168-71.
6. Åkerlund M, Brouard R, Bossmar T, Kostrzewska A, Laudanski T, Lemancewicz A, et al. Receptor binding of oxytocin and vasopressin antagonists and the inhibitory effects on isolated myometrium from preterm and term pregnant women. Br J Obstet Gynaecol. 1999;106:1047-53.
7. Bossmar T, Åkerlund M, Fantoni G, Maggi M, Szamatowics J, Laudanski T. Receptor-mediated uterine effects of oxytocin and vasopressin in non-pregnant women. Br J Obstet Gynaecol. 1995;102:907-12.
8. 1a receptor antagonist on vasopressin-induced uterine contractions in women. Br J Obstet Gynecol. 1997;104:471-7.
9. Åkerlund M. Can primary dysmenorrhoea be alleviated by a vasopressin antagonist? Acta Obstet Gynecol Scand. 1987;66:459-61.
10. 1a receptor antagonist, in the treatment of dysmenorrhoea. Br J Obstet Gynaecol. 2000;107:614-9.
11. Liedman R, Skillern L, James I, Mclead A, Grant L, Åkerlund M. Validation of a test model of induced dysmenorrhoea. Acta Obstet Gynecol Scand. in press.
12. Hauksson A, Åkerlund M, Melin P. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist. Br J Obstet Gynaecol. 1988;95:898-904.
13. Amsterdam EA, Deedwania P. Bedside evaluation of cardiac markers. Point-of-care testing can differentiate acute coronary syndromes. Postgraduate Medicine online. 2005;118(3).
14. Komukai K, Shibata T, Mochizuki S. C-reactive protein is related to impaired oxygenation in patients with acute aortic dissection. Int Heart J. 2005;46:795-9.
15. Chan WY, Levi R, Wo NC, Koyama M, Stoev S, Cheng LL, et al. Novel selective hypotensive vasopressin peptides: cardiovascular and structure-activity-relationship studies. Eur J Pharmacol. 2001;4:65-72.
16. Widholm O, Kantero RL. Menstrual patterns of adolescent girls according to the chronological and gynaecological ages. Acta Obstet Gynecol Scand. 1971;50(Suppl 14):19-29.
17. Thorbert G, Alm P, Björklund AB, Owman C, Sjöberg NO. Adrenergic innervation of the human uterus. Disappearance of the transmitter and transmitter-forming enzymes during pregnancy. Am J Obstet Gynecol. 1979;135:223-6.
18. Lundström V, Gréen K, Wiqvist N. Prostaglandins, indomethacin and dysmenorrhoea. Prostaglandins. 1976;11:893-904.
19. Bitner M, Kattenhorn J, Hatfield C, Gao J, Kellstein D. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract. 2004;58:340-5.